Publicaciones en las que colabora con Olalla Maroñas Amigo (8)

2024

  1. Role of CYP2D6 and CYP3A4 polymorphisms on aripiprazole and dehydroaripiprazole concentrations in patients undergoing long-acting treatment

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 135

  2. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling

    Psychiatry Research, Vol. 333

2023

  1. Influence of Genetic Polymorphisms on the Short-Term Response to Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration

    Investigative ophthalmology & visual science, Vol. 64, Núm. 13, pp. 34

2021

  1. Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics

    Pharmaceutics, Vol. 13, Núm. 7

2020

  1. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 8, pp. 1661-1666

  2. Anti-VEGF treatment and response in age-related macular degeneration: Disease’s susceptibility, pharmacogenetics and pharmacokinetics

    Current Medicinal Chemistry, Vol. 27, Núm. 4, pp. 549-569

  3. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study

    Pharmacotherapy, Vol. 40, Núm. 1, pp. 17-25

2019

  1. Pharmacokinetics of intravitreal anti-VEGF drugs in age-related macular degeneration

    Pharmaceutics, Vol. 11, Núm. 8